HopeStage
Back to all studies
CompletedNCT03166501

Lanicemine for Hyperarousal in PTSD: A Placebo-Controlled Study

About this titleRead the official source — NCT03166501
Medication studyAges 21–65United States
The study in practice

Understand this study

Who was this study for?

This study was for people with PTSD. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.

Listed locations
HoustonSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: September 1, 2018
Recruitment status
Completed
Enrollment listed in the registry
24
Sponsor
Baylor College of Medicine
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 21 Years to 65 Years
Official registry ID
NCT03166501
Official title
Show the full official title

NMDA Receptor Modulation for Hyperarousal in PTSD

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Houston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Baylor College of Medicine, a university.

Did this study involve medication?

Yes. The study involved medication, including Lanicemine and Placebo.

Who was this study for?

This study was for people with PTSD. Listed age limits: 21 years to 65 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies